Atriva Therapeutics announces first closing of series A financing round
Atriva Therapeutics, a biopharmaceutical company pioneering the development of host-targeting antiviral therapies, announced the first closing in its ongoing Series A financing round lead by Meneldor and High-Tech Gründerfonds (HTGF). The Company founders and management joined the round, also. These funds will be focused to prepare first-in-humans clinical testing of the Company’s lead product candidate ATR-002, to be started in 2019. ATR-002 is a first-in-class host-targeting inhibitor of viral replication in influenza and other respiratory infections, an important area of high unmet medical need. The Company will secure additional series A funds for the Phase I and Phase II development of ATR-002 through proof of concept trials.
During 2018, Atriva Therapeutics successfully completed preclinical development of ATR-002 and recently filed a request for scientific advice from a European regulatory authority to provide guidance on the executed preclinical development program and the planned ATR-002 Phase I study in healthy volunteers.
The Company is now advancing ATR-002 towards full clinical development, focusing on patients with influenza at high risk of developing complications. ATR-002 is a MEK inhibitor, targeting a fundamental cellular protein of the replication pathway of influenza-causing viruses and other respiratory viral infections. MEK inhibitors have shown high potential as efficacious and safe antiviral drugs to address the need for a novel, broadly active and resistance-avoiding influenza therapy.
“This first closing is a strong show of support for our novel host-targeting approach in influenza therapy and is a very encouraging signal for the ongoing series A financing round. We are excited that our technology is attracting great interest among potential partners and leading specialist venture capital firms,” said Dr. Rainer Lichtenberger, co-founder and CEO of Atriva Therapeutics. “Clinical trial preparations are ongoing, and we look forward to the next important milestones in the validation of our unique therapeutic approach.”
Other news from the department business & finance
Most read news
More news from our other portals
Something is happening in the life science industry ...
This is what true pioneering spirit looks like: Plenty of innovative start-ups are bringing fresh ideas, lifeblood and entrepreneurial spirit to change tomorrow's world for the better. Immerse yourself in the world of these young companies and take the opportunity to get in touch with the founders.
Last viewed contents
Sartorius acquires cell culture specialist Xell AG - Extension of the Sartorius cell culture media business with a focus on media for gene therapeutics and vaccines
The breakthrough that could lead to new obesity treatments - How a protein could burn off excess calories from fat and sugar
Merck Wins SINGULAIR Patent Infringement Lawsuit
Plate reader for drug discovery
Finnish researchers discover genes inhibiting the spread of prostate cancer
EHEC outbreak: BfR confirms contamination of sprouts with O104:H4 - Strain from the sprouts is identical to strain from the infected patients
Quantifoil Instruments opens door to Korean Market
